Compare TRIN & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRIN | ABCL |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | Canada |
| Employees | 109 | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | 2020 |
| Metric | TRIN | ABCL |
|---|---|---|
| Price | $16.84 | $5.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $16.00 | $8.40 |
| AVG Volume (30 Days) | 941.6K | ★ 6.5M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 12.61% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | $30.41 | N/A |
| Revenue Next Year | $10.00 | $21.85 |
| P/E Ratio | $7.18 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $13.76 | $2.75 |
| 52 Week High | $17.38 | $6.79 |
| Indicator | TRIN | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 53.87 |
| Support Level | $16.56 | $5.34 |
| Resistance Level | $17.31 | $5.63 |
| Average True Range (ATR) | 0.29 | 0.52 |
| MACD | -0.05 | -0.08 |
| Stochastic Oscillator | 18.80 | 24.44 |
Trinity Capital Inc is an internally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, capital appreciation through investments across five distinct vertical markets. The company is focused on achieving its investment objective by operating as a specialty lending company that provides debt, including loans, equipment financings, and asset-based lending, to growth-oriented companies, including institutional investor-backed companies. Its investment portfolio mainly comprises private companies that have begun to have success selling their products to the market and need additional capital to expand their operations and sales.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.